CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Erchonia EVRLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05091047
NCT05091047N/ACompleted

A Pilot Evaluation of the Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain

Erchonia Corporation·interventional·Posted Oct 25, 2021·Updated Jun 6, 2022

In Brief

A clinical study evaluating Erchonia EVRL for Neuropathy. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This study is to see if applying red and violet low-level laser light can help to reduce foot pain associated with diabetic peripheral neuropathy,

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathy
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 25, 2021
Enrollment StartJun 16, 2021
Primary CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.7 years ago

Interventions

Erchonia EVRLdevice

42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.